Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The aim of this study is to survey the effectiveness of preservative-free artificial tears containing hyaluronic acid (HA) on post-cataract surgery dry eye disease (DED) prevention. A retrospective cohort study was performed, and patients that received cataract surgeries were divided into either an HA group or non-HA group depending on the artificial tear they used. A total of 37 and 74 eyes were enrolled into the HA and non-HA groups, respectively, after the selection. The primary outcomes are postoperative superficial keratitis and multiple (>3) DED symptoms. The generalized linear model was utilized to calculate the adjusted odds ratio (aOR) and 95% confidence interval (CI) of primary outcomes between the two groups. There were 10 and 2 episodes of superficial keratitis in the non-HA group and HA group, respectively, and the HA group demonstrated a significantly lower incidence of superficial keratitis ( < 0.001). Moreover, 13 and 5 patients developed multiple DED symptoms in the non-HA and HA groups, and the HA group illustrated fewer multiple DED symptoms ( = 0.024). The lower preoperative tear break-up time (TBUT) was correlated with superficial keratitis in the HA group ( = 0.043), while old age, low preoperative TBUT and ocular surface staining were associated with superficial keratitis in the non-HA group (all < 0.05). Lower preoperative TBUT was correlated with multiple DED symptoms in the HA group ( = 0.020), while female sex, low preoperative TBUT and any DED symptoms were associated with multiple DED symptoms in the non-HA group (all < 0.05). In conclusion, the usage of preservative-free artificial tears containing HA is associated with lower postoperative DED events.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11393976PMC
http://dx.doi.org/10.3390/diagnostics14171848DOI Listing

Publication Analysis

Top Keywords

ded symptoms
24
superficial keratitis
20
multiple ded
20
non-ha group
16
preservative-free artificial
12
artificial tears
12
preoperative tbut
12
group
10
tears hyaluronic
8
hyaluronic acid
8

Similar Publications

Introduction: Chronic ocular surface pain (COSP) is defined as ocular pain that is perceived to originate from the ocular surface and persists for more than 3 months. Clear epidemiological data on COSP prevalence are lacking.

Methods: In 2025, a total of 100 eye care providers were surveyed, including 50 optometrists and 50 ophthalmologists.

View Article and Find Full Text PDF

Dry eye disease (DED) is a chronic inflammatory condition with increasing prevalence. Current treatment strategies, including artificial tears and anti-inflammatory agents, often fail to fully relieve ocular discomfort or meet patients' broader clinical needs. Psychosomatic medicine is grounded in the biopsychosocial model of disease.

View Article and Find Full Text PDF

Purpose: This study aimed to revise data published in the literature on the effects of cataract surgery on tear film characteristics, in relation to personal clinical surgical experience.

Methods: A search was undertaken using PubMed (all years). Search terms included 'cataract surgery', 'phacoemulsification', 'cataract extraction', and 'manual small-incision cataract surgery', combined at first with 'ocular surface' and 'lacrimal film'.

View Article and Find Full Text PDF

Background: Dry eye disease (DED) represents a multifactorial condition characterized by ocular discomfort and visual disturbances. The management of DED relies heavily on accurate diagnosis to tailor effective treatments. Diagnostic approaches encompass both subjective and objective assessments.

View Article and Find Full Text PDF

Purpose: Sex hormone changes, often occurring during menopause, are implicated in meibomian gland dysfunction (MGD) and evaporative dry eye disease (DED). This study aimed to evaluate whether menopausal status affects the treatment outcomes of perfluorohexyloctane eye drops.

Methods: This post hoc analysis used data from a phase 3 trial (NCT05515471) of perfluorohexyloctane eye drops in patients with DED associated with MGD.

View Article and Find Full Text PDF